This HTML5 document contains 183 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/mesh/concept/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/drugbank/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n26http://www.drugs.com/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/national-drug-code-directory/
n27http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/chemspider/
n8http://www.rxlist.com/cgi/generic/
n10http://linked.opendata.cz/resource/drugbank/patent/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/kegg-compound/
n12http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00425/identifier/bindingdb/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00425
rdf:type
n3:Drug
n3:description
Zolpidem is a prescription short-acting nonbenzodiazepine hypnotic that potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by binding to benzodiazepine receptors which are located on the gamma-aminobutyric acid receptors. Zolpidem is used for the short-term treatment of insomnia. It works quickly (usually within 15 minutes) and has a short half-life (2-3 hours). It is classified as an imidazopyridine. As an anticonvulsant and muscle relaxant, the beneficial effects start to emerge at 10 and 20 times the dose required for sedation, respectively. For that reason, it has never been approved for either muscle relaxation or seizure prevention. Recently, zolpidem has been cited in various medical reports mainly in the United Kingdom as waking persistent vegetative state (PVS) patients, and dramatically improving the conditions of people with brain injuries. [Wikipedia]
n3:dosage
n15:271B4BAA-363D-11E5-9242-09173F13E4C5 n15:271B4BAB-363D-11E5-9242-09173F13E4C5 n15:271B4BAC-363D-11E5-9242-09173F13E4C5 n15:271B4BAD-363D-11E5-9242-09173F13E4C5 n15:271B4BAE-363D-11E5-9242-09173F13E4C5 n15:271B4B9F-363D-11E5-9242-09173F13E4C5 n15:271B4BA0-363D-11E5-9242-09173F13E4C5 n15:271B4BA1-363D-11E5-9242-09173F13E4C5 n15:271B4BA2-363D-11E5-9242-09173F13E4C5 n15:271B4BA3-363D-11E5-9242-09173F13E4C5 n15:271B4BA4-363D-11E5-9242-09173F13E4C5 n15:271B4BA5-363D-11E5-9242-09173F13E4C5 n15:271B4BA6-363D-11E5-9242-09173F13E4C5 n15:271B4BA7-363D-11E5-9242-09173F13E4C5 n15:271B4BA8-363D-11E5-9242-09173F13E4C5 n15:271B4BA9-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Lemmer B: The sleep-wake cycle and sleeping pills. Physiol Behav. 2007 Feb 28;90(2-3):285-93. Epub 2006 Oct 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17049955 # Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G: Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther. 1986 May;237(2):649-58. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2871178 # Clauss RP, Guldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR: Extraordinary arousal from semi-comatose state on zolpidem. A case report. S Afr Med J. 2000 Jan;90(1):68-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10721397 # Schlich D, L'Heritier C, Coquelin JP, Attali P, Kryrein HJ: Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res. 1991 May-Jun;19(3):271-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1670039 # Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL: The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res. 1992 Apr;20(2):162-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1521672
n3:group
approved
n3:halfLife
2.6 hours
n3:indication
For the short-term treatment of insomnia.
n3:manufacturer
n9:271B4B8E-363D-11E5-9242-09173F13E4C5 n9:271B4B8C-363D-11E5-9242-09173F13E4C5 n9:271B4B8D-363D-11E5-9242-09173F13E4C5 n9:271B4B8B-363D-11E5-9242-09173F13E4C5 n9:271B4B82-363D-11E5-9242-09173F13E4C5 n9:271B4B83-363D-11E5-9242-09173F13E4C5 n9:271B4B80-363D-11E5-9242-09173F13E4C5 n9:271B4B81-363D-11E5-9242-09173F13E4C5 n9:271B4B7E-363D-11E5-9242-09173F13E4C5 n9:271B4B7F-363D-11E5-9242-09173F13E4C5 n9:271B4B7C-363D-11E5-9242-09173F13E4C5 n9:271B4B7D-363D-11E5-9242-09173F13E4C5 n9:271B4B8A-363D-11E5-9242-09173F13E4C5 n9:271B4B8F-363D-11E5-9242-09173F13E4C5 n9:271B4B88-363D-11E5-9242-09173F13E4C5 n9:271B4B89-363D-11E5-9242-09173F13E4C5 n9:271B4B86-363D-11E5-9242-09173F13E4C5 n9:271B4B87-363D-11E5-9242-09173F13E4C5 n9:271B4B84-363D-11E5-9242-09173F13E4C5 n9:271B4B85-363D-11E5-9242-09173F13E4C5 n9:271B4B94-363D-11E5-9242-09173F13E4C5 n9:271B4B92-363D-11E5-9242-09173F13E4C5 n9:271B4B93-363D-11E5-9242-09173F13E4C5 n9:271B4B90-363D-11E5-9242-09173F13E4C5 n9:271B4B91-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00425 n27:DB00425
dcterms:title
Zolpidem
adms:identifier
n17:26266 n18:10125 n19:46507949 n20:PA451976 n21:5732 n22:C07219 n23:54868-0845-0 n24:5530 n25:DB00425 n29:Zolpidem
n3:mechanismOfAction
Zolpidem modulates the alpha-subunit, known as the benzodiazepine receptor, within the GABA<sub>A</sub> receptor chloride channel macromolecular complex. Unlike the benzodiazepines, which non-selectively interact with all three alpha-receptor subtypes, Zolpidem preferentially binds to the alpha-1 receptor.
n3:packager
n9:271B4B66-363D-11E5-9242-09173F13E4C5 n9:271B4B64-363D-11E5-9242-09173F13E4C5 n9:271B4B65-363D-11E5-9242-09173F13E4C5 n9:271B4B5E-363D-11E5-9242-09173F13E4C5 n9:271B4B5F-363D-11E5-9242-09173F13E4C5 n9:271B4B5C-363D-11E5-9242-09173F13E4C5 n9:271B4B5D-363D-11E5-9242-09173F13E4C5 n9:271B4B62-363D-11E5-9242-09173F13E4C5 n9:271B4B63-363D-11E5-9242-09173F13E4C5 n9:271B4B75-363D-11E5-9242-09173F13E4C5 n9:271B4B60-363D-11E5-9242-09173F13E4C5 n9:271B4B61-363D-11E5-9242-09173F13E4C5 n9:271B4B73-363D-11E5-9242-09173F13E4C5 n9:271B4B74-363D-11E5-9242-09173F13E4C5 n9:271B4B5A-363D-11E5-9242-09173F13E4C5 n9:271B4B5B-363D-11E5-9242-09173F13E4C5 n9:271B4B59-363D-11E5-9242-09173F13E4C5 n9:271B4B54-363D-11E5-9242-09173F13E4C5 n9:271B4B44-363D-11E5-9242-09173F13E4C5 n9:271B4B45-363D-11E5-9242-09173F13E4C5 n9:271B4B42-363D-11E5-9242-09173F13E4C5 n9:271B4B43-363D-11E5-9242-09173F13E4C5 n9:271B4B48-363D-11E5-9242-09173F13E4C5 n9:271B4B49-363D-11E5-9242-09173F13E4C5 n9:271B4B46-363D-11E5-9242-09173F13E4C5 n9:271B4B47-363D-11E5-9242-09173F13E4C5 n9:271B4B3D-363D-11E5-9242-09173F13E4C5 n9:271B4B40-363D-11E5-9242-09173F13E4C5 n9:271B4B41-363D-11E5-9242-09173F13E4C5 n9:271B4B3E-363D-11E5-9242-09173F13E4C5 n9:271B4B3F-363D-11E5-9242-09173F13E4C5 n9:271B4B76-363D-11E5-9242-09173F13E4C5 n9:271B4B77-363D-11E5-9242-09173F13E4C5 n9:271B4B71-363D-11E5-9242-09173F13E4C5 n9:271B4B72-363D-11E5-9242-09173F13E4C5 n9:271B4B7A-363D-11E5-9242-09173F13E4C5 n9:271B4B7B-363D-11E5-9242-09173F13E4C5 n9:271B4B78-363D-11E5-9242-09173F13E4C5 n9:271B4B79-363D-11E5-9242-09173F13E4C5 n9:271B4B6B-363D-11E5-9242-09173F13E4C5 n9:271B4B6C-363D-11E5-9242-09173F13E4C5 n9:271B4B69-363D-11E5-9242-09173F13E4C5 n9:271B4B6A-363D-11E5-9242-09173F13E4C5 n9:271B4B6F-363D-11E5-9242-09173F13E4C5 n9:271B4B70-363D-11E5-9242-09173F13E4C5 n9:271B4B6D-363D-11E5-9242-09173F13E4C5 n9:271B4B6E-363D-11E5-9242-09173F13E4C5 n9:271B4B55-363D-11E5-9242-09173F13E4C5 n9:271B4B56-363D-11E5-9242-09173F13E4C5 n9:271B4B52-363D-11E5-9242-09173F13E4C5 n9:271B4B53-363D-11E5-9242-09173F13E4C5 n9:271B4B67-363D-11E5-9242-09173F13E4C5 n9:271B4B68-363D-11E5-9242-09173F13E4C5 n9:271B4B57-363D-11E5-9242-09173F13E4C5 n9:271B4B58-363D-11E5-9242-09173F13E4C5 n9:271B4B4C-363D-11E5-9242-09173F13E4C5 n9:271B4B4D-363D-11E5-9242-09173F13E4C5 n9:271B4B4A-363D-11E5-9242-09173F13E4C5 n9:271B4B4B-363D-11E5-9242-09173F13E4C5 n9:271B4B50-363D-11E5-9242-09173F13E4C5 n9:271B4B51-363D-11E5-9242-09173F13E4C5 n9:271B4B4E-363D-11E5-9242-09173F13E4C5 n9:271B4B4F-363D-11E5-9242-09173F13E4C5
n3:patent
n10:6514531 n10:7632517
n3:routeOfElimination
Zolpidem tartrate tablets are converted to inactive metabolites that are eliminated primarily by renal excretion.
n3:synonym
Zolpidemum Zolpidem N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
n3:toxicity
Oral (male rat) LD<sub>50</sub> = 695 mg/kg. Symptoms of overdose include impairment of consciousness ranging from somnolence to light coma.
n3:foodInteraction
Avoid alcohol. Should not be administered with or immediately after a meal.
n3:proteinBinding
92.5 &plusmn; 0.1% (independent of concentration between 40 and 790 ng/mL)
n3:salt
n3:synthesisReference
Markus Sauter, "Process for preparing zolpidem." U.S. Patent US20020183522, issued December 05, 2002.
n5:hasConcept
n6:M0140872
foaf:page
n8:zolpid.htm n26:zolpidem.html
n3:IUPAC-Name
n4:271B4BB3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4BB9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4BB8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4BB5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4BB6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4BB7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4BB1-363D-11E5-9242-09173F13E4C5 n4:271B4BC8-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4BB2-363D-11E5-9242-09173F13E4C5 n4:271B4BCA-363D-11E5-9242-09173F13E4C5 n4:271B4BAF-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4BB0-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4BCB-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:N05CF02
n3:H-Bond-Acceptor-Count
n4:271B4BBF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4BC0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4BBA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4BBB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4BBD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4BBC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4BBE-363D-11E5-9242-09173F13E4C5
n3:absorption
Zolpidem is rapidly absorbed from the GI tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
82626-48-0
n3:category
n3:containedIn
n28:271B4B9A-363D-11E5-9242-09173F13E4C5 n28:271B4B9B-363D-11E5-9242-09173F13E4C5 n28:271B4B9E-363D-11E5-9242-09173F13E4C5 n28:271B4B96-363D-11E5-9242-09173F13E4C5 n28:271B4B97-363D-11E5-9242-09173F13E4C5 n28:271B4B95-363D-11E5-9242-09173F13E4C5 n28:271B4B9C-363D-11E5-9242-09173F13E4C5 n28:271B4B9D-363D-11E5-9242-09173F13E4C5 n28:271B4B98-363D-11E5-9242-09173F13E4C5 n28:271B4B99-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4BC4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4BC6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4BC7-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4BC9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4BC3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4BC2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4BC5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4BB4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4BC1-363D-11E5-9242-09173F13E4C5